SavedAdd your journal

Journals / Turkish Journal of Hematology / 2009 / Cilt: 26 - Sayı: 4

Medikal hastalarda anti-heparin trombosit faktör 4 antikor ve heparine bağlı trombositopeni sıklığ

Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients

Muzaffer DEMİR
Emre TEKGÜNDÜZ
Mustafa EDİS
Enver DURAN
Turan KÜRÜM
Ömer YİĞİTBAŞI
MAHMUT YÜKSEL
Pages
171–175
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Seroconversion rates by means of antigenic and functional assays and clinical HIT were more common in patients on UFH than patients on LMWH therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Heparin-induced thrombocytopenia (HIT) is a life threatening complication of heparin therapy, causing thrombosis.
📊
Key Findings & Data:Materials and Methods: Our study included 61 patients who were on unfractionated heparin (UFH) (n: 37) and low molecular weight heparin (LMWH) (n: 24) therapies.
💡
Conclusion & Impact:Conclusion: Seroconversion rates by means of antigenic and functional assays and clinical HIT were more common in patients on UFH than patients on LMWH therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İleriye dönük çalışma · Türkiye · Görülme sıklığı

Abstract

Objective: Heparin-induced thrombocytopenia (HIT) is a life threatening complication of heparin therapy, causing thrombosis. The aim of our study was to find out the frequencies of HIT antibody seroconversion and clinical HIT in Turkish medical patients on different forms of heparins. Materials and Methods: Our study included 61 patients who were on unfractionated heparin (UFH) (n: 37) and low molecular weight heparin (LMWH) (n: 24) therapies. The frequency of HIT antibody formation was determined by means of antigenic (ELISA), and functional assays (serotonin release assay-SRA). Results: The seroconversion rates in UFH and LMWH groups were found to be 18.9% and 4.1% (ELISA), and 8.1% and 4.1% (SRA), respectively. One patient (2.1%) on UFH therapy developed deep vein thrombosis. No thromboembolic event was observed in patients taking LMWH. Conclusion: Seroconversion rates by means of antigenic and functional assays and clinical HIT were more common in patients on UFH than patients on LMWH therapy.

Özet

Amaç: Heparine bağlı trombositopeni (HİT) heparin tedavisinin tromboza neden olan, hayatı tehdit eden bir komplikasyo- nudur. Çalışmamızın amacı farklı heparin formları kullanan dahili Türk hastalarda HİT antikor serokonversiyonu ve klinik HİT sıklığının saptanmasıydı. Yöntem ve Gereçler: Çalışmamıza anfraksiyone heparin (AFH) (n: 37) ve düşük molekül ağırlıklı heparin (DMAH) (n: 24) tedavisi alan 61 hasta katıldı. HIT antikor oluşumu antijenik (ELISA) ve fonksiyonel (serotonin salınım testi-SRA) testler ile değerlendirildi. Bulgular: AFH ve DMAH gruplarında serokonversiyon oranları sırasıyla %18,9-%4,1 (ELISA) ve %8,1-%4,1 (SRA) saptandı. AFH kullanan bir hastada (%2,1) derin ven trombozu gelişti. DMh kullanan hastalarda tromboembolik olay izlenmedi. Sonuç: aFH kullanan hastalarda dmah kullananlara göre antijenik ve fonksiyonel yöntemlerle serokonversiyon ve klinik HIT oranları daha yüksek saptandı.

🔖

Cite This Article

DEMİR, M., TEKGÜNDÜZ, E., EDİS, M., DURAN, E., KÜRÜM, T., YİĞİTBAŞI, Ö., YÜKSEL, M. (2009). Medikal hastalarda anti-heparin trombosit faktör 4 antikor ve heparine bağlı trombositopeni sıklığ. Turkish Journal of Hematology, Cilt: 26 - Sayı: 4, 171–175. https://ajindex.com/articles/413010

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Warkentin TE. Think of HIT. Hematology (Am Soc Hematol Educ Prog) 2006;408-14
  2. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost.1999; 82: 439-47
  3. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin N Am 2007;21:589-607
  4. Rice L. Heparin-induced thrombocytopenia. Myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med. 2004;164:1961-4
  5. Greinacher A, Eichler P, Lubenow N, Kwasyn H, Luz M. Heparininduced thrombocytopenia with thromboembolic complications: metaanalysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51
  6. Kuo KHM, Kovacs MJ. Fondaparinux: A potential new therapy for HIT. Hematology 2005;10:271-75
  7. Girolami B, Prandoni P, Stefani PM, Tandou C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003;101:2955-9
  8. Prandoni P, Siragusa S, Girolami B, Fabris F. BELZONI Investigators Group. The incidence of heparin-inducedthrombocytopenia in medical patients treated with low- molecular-weight heparin: a prospective cohort study. Blood 2005;106:3049-54
  9. Walenga JM, Jeske WP, Fasanella AR, Wood JJ, Bakhos M. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999; 25 (Suppl 1): S43-9
  10. Demir M, Ahmad S, Walenga JM, Fareed J. Laboratory diagnosis of heparin-induced thrombocytopenia. Turk J Haematol 2000;17(3 Suppl 3):181-90
  11. Warkentin T and Sheppard JAI. Testing for HIT antibodies. Transfusion Medicine Reviews 2006; 20: 259-72
  12. Demir M, Duran E, Yigitbasi O, Vural O, Kurum T, Yuksel M, Turgut B, Walenga JM, Fareed J. Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery. Clin Appl Thromb Hemost 2007;13:279-84
  13. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet agregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69:344-50
  14. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin induced thrombocytopenia. Blood 1986;67:27-30
  15. Warkentin TE, Greinacher A, Koster A and Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. The 8th ACCP conference on anti